Skip to main content
. 2016 Jul 1;23(7):848–856. doi: 10.5551/jat.33407

Fig. 1.

Fig. 1.

Percentage changes in LDL cholesterol, hetero-dimer PCSK9, and sortilin levels at the 8-month follow-up.

Although the reduction in LDL cholesterol levels was greater in the pitavastatin group than in the pravastatin group, no significant differences in percentage changes in hetero-dimer PCSK9 and sortilin were observed. Data are expressed as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.0001 compared with baseline.